Loading…
← CockpitCompetitor Analysis › 000640.KS Dong-A Socio Holdings Co., Ltd.Open in the cockpit ↗

Dong-A Socio Holdings Co., Ltd.000640.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Pharmaceuticals: Major
Momentum strong 79
Mkt cap
$447M
US dollars, full cap
Free float
49%
of shares outstanding
$/day
$716,213
20-day average traded
Fwd P/E
7.3×
forward earnings
ROIC−WACC
-0.4 pp
WACC 5.0%
Hurdle
-19 pp
Req g minus delivered
Next earnings
89 days
15 Feb 2027
Close · KRW₩88,800
1D+0.3%
1W-1.0%
1M-4.3%
3M-4.5%
6M-8.2%
YTD-16.6%
1Y-16.3%
ATR %3.7%
52w lowhigh27.1% off high

What Dong-A Socio does

Employees: 82

Dong-A Socio at a glance

Size Dong-A Socio (000640.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $447M, the 377th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩88,800 on 18 Nov 2026.

Performance Over six months the shares fell 8.2%, against -21.3% for the median peer and -37.2% for the South Korea market (cap-weighted) — 5th highest of 20 in its peer set.

Growth Revenue grew 11.5% over the last twelve months (peer median +4.9%); the operating margin is 7.0% (peer median 4.3%).

Valuation It trades at 7.3× forward earnings against a peer median of 23.1× (cheapest of 6).

Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -19 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.4 points below its cost of capital (5.0% WACC).

Next results Next results expected around 15 Feb 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026000640.KS 93Peer median 79
Six months, rebased to 100: Dong-A Socio against the median of its 20 peers (local-currency closes).

Dong-A Socio financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩1.57T₩1.43T₩1.33T₩1.13T₩1.01T
Revenue growth—+7%+18%+12%—
Gross profit₩485B₩439B₩396B₩364B₩283B
EBITDA₩202B₩193B₩171B₩151B₩109B
Net income₩69.6B₩90.9B₩58.0B₩58.0B₩11.2B
Free cash flow₩99.8B₩154B₩12.2B-₩3.54B₩9.12B
Capital expenditure₩73.9B₩58.6B₩71.9B₩153B₩78.6B
Total debt₩699B₩663B₩740B₩692B₩552B

Quarterly statements and history in the cockpit →

Dong-A Socio competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%0%+20%603811603566RPGLIFEGUFICBIO002462000788000518ASMB688136605077688117PHAT002693KPLCAPR600613000640.KS6-month return →1-month return →
Up and to the right = strong over both horizons. Dong-A Socio is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%10×20×30×40×603566688136605077688117PHAT000640.KSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Dong-A Socio is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%603811603566002462000788688117002693002923600613000640.KSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Dong-A Socio is the large dot.

Dong-A Socio competitors and peer comparison

How Dong-A Socio compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Dong-A Socio against its 20 peers (data as of 18 Nov 2026)
Measure000640.KSPeer medianRank in peer set
1-month return-4.3%-11.1%7th highest of 21
6-month return-8.2%-21.3%5th highest of 20
Distance from 52-week high-27.1%-46.0%4th highest of 21
Revenue growth (TTM)+11.5%+4.9%10th highest of 20
Operating margin7.0%4.3%7th highest of 19
Forward P/E7.3×23.1×cheapest of 6
Growth the price implies (Req g, 7 yrs)-6.6%1.4%2nd least demanding of 9
Growth delivered (Del g)+12.8%+1.1%2nd highest of 9
Hurdle (Req g minus delivered)-19.4 pp+0.7 ppleast demanding of 9
ROIC minus cost of capital-0.4 pp-2.1 pp8th highest of 19
EV / EBITDA5.5×25.9×cheapest of 4
Net debt / EBITDA2.5×0.9×most indebted of 4

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Dong-A Socio 000640.KSSouth Korea$447M-8%+11%7%7.3×-6.6%+12.8%
Zhejiang Chengyi Pharmaceutical 603811.SSChina$445M-21%+5%19%n/a1.3%+1.3%
Pulike Biological Engineering 603566.SSChina$449M-21%-9%5%23.2×4.5%+3.3%
RPG Life Sciences RPGLIFE.NSIndia$443M+10%+15%17%n/an/an/a
Gufic Biosciences GUFICBIO.NSIndia$452M+48%+17%14%n/an/an/a
Cachet Pharmaceutical 002462.SZChina$441M-25%-14%0%n/a-9.9%-3.4%
Harbin Medisan Pharmaceutical 002900.SZChina$437M-16%-5%-29%n/an/an/a
PKU Healthcare 000788.SZChina$437M-12%-49%5%n/a-5.6%-5.6%
Jiangsu Sihuan Bioengineering 000518.SZChina$437M-8%-17%-28%n/an/an/a
Assembly Biosciences ASMBUnited States$458M-15%+80%-32%n/an/an/a
Kexing Biopharm 688136.SSChina$433M-42%-14%-12%23.1×n/an/a
Zhejiang Huakang Pharmaceutical 605077.SSChina$433M-47%+35%4%10.3×n/an/a
Cheng Du Sheng Nuo Biotec 688117.SSChina$433M-48%+51%27%12.5×-0.2%+14.5%
Phathom Pharmaceuticals PHATUnited States$431M-55%+87%-9%39.5×n/an/a
BlossomHill Therapeutics BLSMUnited States$464Mn/an/an/an/an/an/a
Hainan Shuangcheng Pharmaceuticals 002693.SZChina$465M-28%+40%13%n/a44.1%+1.0%
Zhuhai Rundu Pharmaceutical 002923.SZChina$430M-30%+14%5%n/a1.4%-1.3%
Kwality Pharmaceuticals KPL.NSIndia$467M+110%+48%22%n/an/an/a
Capricor Therapeutics CAPRUnited States$467M-70%-100%n/an/an/an/a
Shanghai Shenqi Pharmaceutical Investment Management 600613.SSChina$427M+4%-4%3%n/a10.6%+1.4%
Zhejiang Yatai Pharmaceutical 002370.SZChina$468M-32%-4%-11%n/an/an/a

Questions

Which companies are Dong-A Socio's closest peers?
The cockpit's peer set: Zhejiang Chengyi Pharmaceutical (603811.SS), Pulike Biological Engineering (603566.SS), RPG Life Sciences (RPGLIFE.NS), Gufic Biosciences (GUFICBIO.NS), Cachet Pharmaceutical (002462.SZ), Harbin Medisan Pharmaceutical (002900.SZ), PKU Healthcare (000788.SZ), Jiangsu Sihuan Bioengineering (000518.SZ).
Is Dong-A Socio expensive compared with its peers?
On forward p/e it trades at 7.3× against a peer median of 23.1×, cheapest of 6 in its peer set. For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -19 pp: the price already allows for a slowdown.
How has Dong-A Socio stock performed?
Over six months to 18 Nov 2026 the shares returned -8.2% against -21.3% for the median peer; over one year -16.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.